Tocilizumab: a therapeutic option for the treatment of Cytokine Storm Syndrome in COVID-19

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.creatorSaha, Abinit-
Autor(es): dc.creatorSharma, Ashish Ranjan-
Autor(es): dc.creatorBhattacharya, Manojit-
Autor(es): dc.creatorSharma, Garima-
Autor(es): dc.creatorLee, Sang-Soo-
Autor(es): dc.creatorChakraborty, Chiranjib-
Data de aceite: dc.date.accessioned2026-02-09T11:22:55Z-
Data de disponibilização: dc.date.available2026-02-09T11:22:55Z-
Data de envio: dc.date.issued2020-06-24-
Data de envio: dc.date.issued2020-06-24-
Data de envio: dc.date.issued2019-
Fonte completa do material: dc.identifierhttps://repositorio.ufla.br/handle/1/41561-
Fonte completa do material: dc.identifierhttps://www.sciencedirect.com/science/article/pii/S0188440920307827-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/capes/1139694-
Descrição: dc.descriptionPresently, we need more therapeutic molecules for this COVID-19 outbreak. The severity and mortality of the disease is associated with a high level of release of cytokine in the patients which is known as CRS (cytokine release syndrome) or cytokine storm syndrome. IL-6 is a type of pro-inflammatory cytokine which release in the severe COVID-19 patients. This cytokine initiates CRS the JAK-STAT or MAPK/NF-κB-IL-6 pathway. Tocilizumab, a humanized monoclonal antibody, is designed to bind both mIL-6R (membrane bound receptor for IL-6) and sIL-6R (soluble receptor for IL-6) and inhibit the JAK-STAT or MAPK/NF-κB-IL-6 signaling pathway. It finally stops the cytokine storm syndrome. However, we need to understand that how tocilizumab is bound with mIL-6R or sIL-6R. Similarly, we also need to understand more about the real molecular mechanism of activity of tocilizumab.-
Idioma: dc.languageen-
Publicador: dc.publisherElsevier-
Direitos: dc.rightsrestrictAccess-
???dc.source???: dc.sourceArchives of Medical Research-
Palavras-chave: dc.subjectTocilizumab-
Palavras-chave: dc.subjectCytokine storm syndrome-
Palavras-chave: dc.subjectCOVID-19-
Título: dc.titleTocilizumab: a therapeutic option for the treatment of Cytokine Storm Syndrome in COVID-19-
Tipo de arquivo: dc.typeArtigo-
Aparece nas coleções:Repositório Institucional da Universidade Federal de Lavras (RIUFLA)

Não existem arquivos associados a este item.